GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum28481ArticlesСтатьиResearch ArticleMelatonin in treatment of climacteric symptomsВозможности терапии климактерических симптомов с помощью препаратов мелатонинаKuznetsovaI VКузнецоваИрина Всеволодовна

д-р мед. наук, проф., глав. науч. сотр. научно-исследовательского отд. женского здоровья Научно-исследовательского центра ГБОУ ВПО Первый МГМУ им. И.М.Сеченова

BurchakovD IБурчаковДенис Игоревич

врач-эндокринолог, сомнолог ФГБУ ЭНЦ

dr.burchakov@yandex.ruI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииEndocrinology research center of the Ministry of Health of the Russian FederationФГБУ Эндокринологический научный центр Минздрава России15102015175VOL 17, NO5 (2015)ТОМ 17, №5 (2015)444809042020Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/28481

During menopausal transition women develop vasomotor and psychosomatic symptoms. These symptoms stem both from estrogen deprivation and hypothalamic-pituitary system ageing. Melatonin is a powerful hormonal adaptogen, working at every level of reproductive system, down to receptor level. To measure its effect on climacteric symptoms, we enrolled 55 women between 45 and 65 y.o. All participants took 3 mg of melatonin - Melaxen (Unipharm, Inc.) for 3 months. During the therapy we observed marked reduction of symptoms from 40.96 to 21.36 (47.92%) on Greene Climacteric Scale and sleep improvement from 16.60±4.03 to 7.33±1.95 on Pittsburgh Sleep Quality Index. Melatonin 3 mg is an effective method of climacteric symptoms therapy.

В период менопаузального перехода у женщин развиваются вазомоторные и психосоматические симптомы. Патогенез этих симптомов связан не только с дефицитом эстрогенов, но и со старением гипоталамо-гипофизарной системы. Мелатонин - мощный гормональный адаптоген, участвующий в работе всех звеньев репродуктивной системы, в том числе на рецепторном уровне. Для оценки его эффективности в терапии климактерических симптомов в исследование были включены 55 женщин в возрасте 45-65 лет. Все участницы исследования получали мелатонин - препарат Мелаксен («Юнифарм, Инк.») в дозе 3 мг в течение 3 мес. На фоне терапии было отмечено уменьшение интенсивности климактерических симптомов по климактерической шкале Грина с 40,96 до 21,36 (47,92%) и улучшение показателей сна по Питтсбургской шкале качества сна с 16,60±4,03 до 7,33±1,95 балла. Таким образом, мелатонин в дозе 3 мг - эффективный метод терапии климактерических симптомов.

menopausal symptomstreatmentmelatoninклимактерические симптомылечениемелатонинКлинические рекомендации. Акушерство и гинекология. Вып. 2. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2008.Genazzani A.R, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric 2007; 10 (2): 88-96.Nelson H.D, Haney E, Humphrey L et al. Management of menopause - related symptoms. Evid Rep Technol Assess (Summ) 2005; 120: 1-6.Сметник В.П., Ильина Л.М. Роль половых гормонов в развитии метаболических расстройств у женщин в пери - и ранней постменопаузе. Климактерий. 2009; 1: 8-13.North American Menopause Society. Treatment of menopause - associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11: 11-33.Col N.F, Guthrie J.R, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle - aged women: a longitudinal study. Menopause 2009; 16:453-7.Politi M.C, Schleinitz M.D, Col N.F. Revisting the duration of vasomotor symptoms of menopause: a meta - analysis. J Gen Intern Med 2008; 23: 1507-13.Freeman E.W, Sammel M.D, Lin H et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 11 (5):1095-104.Loprinzi C.L, Barton D.L. On hot flash mechanism, measurement, and treatment. Menopause 2009; 16: 621-3.Freedman R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005; 23 (2): 117-25.Skurnick J.H, Weiss G, Goldsmith L.T et al. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms. Fertil Steril 2009; 91 (4):1127-34.Rapkin A.J. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007; 196: 97-106.Freedman R.R, Benton M.D, Genic R.J, Graydon F.X. Cortical activation during menopausal hot flashes. Fertil Steril 2006; 85: 674-8.Freeman E.W, Sammel M.D, Lin H et al. The role of anxiety and hormonal changes in menopausa hot flashes. Menopause 2005; 12: 258-66.Juang K.D, Wang S.J, Lu S.R et al. Hot flashes are associated with psychological symptoms of anxiety and depression in peri - and post - but not premenopausal women. Maturitas 2005; 52: 119-26.Hodis H.N, Mack W.J. Postmenopausal hormone therapy in clinical perspective. Menopause, 2007; 14 (5): 944-57.Sturdee D.W et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302-20.Gompel A, Rozenberg S, Barlow D.H. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008; 61: 227-32.Hill D.A, Hill S.R. Counseling patients about hormone therapy and alternatives for menopausal symptoms. Am Fam Physician 2010; 82: 801-7.Tsai S.A, Stefanick M.L, Stafford R.S. Trends in menopausal hormone therapy use of US office - based physicians, 2000-2009. Menopause 2011; 18: 385-92.Kronenberg F, Cushman L.F, Wade C.M et al. Race/ethnicity and women`s use of complementary and alternative medicine in the United States: results of national survey. Am J Public Health 2006; 96: 1236-42.Reddy S.Y, Warner H, Gutusso T et al. Gabapentin, estrogen and placebo for treating hot flashes. Obstet Gynecol 2006; 108: 41-8.Fonken L.K, Randy J.N. The effects of light at night on circadian clocks and metabolism. Endocr Rev 2014; 35 (4): 648-70.Tamura H, Takasaki A, Taketani T et al. Melatonin and female reproduction. J Bstet Gynaecol Res 2014; 40: 1-11.Hill S, Belancio V, Dauchy R et al. Melatonin: an Inhibitor of Breast Cancer. Endocr Relat Cancer 2015; 22: 183-204.Tsutsui K, Ubuka T, Bentley G et al. Review: regulatory mechanisms of gonadotropin - inhibitory hormone (GnIH) synthesis and release in photoperiodic animals. Front Neurosci 2013; 7: 60.Toffol E, Kallenen N, Haukka J et al. Melatonin in perimenopausal and postmenopausal Women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause 2014; 21 (5): 493-500.Greene J. Constructing a standard climacteric scale. Maturitas 2008; 61: 78-84.Nunes D, Mota R, Machado M. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res 2008; 41: 926-31.Bruyneel M. Sleep disturbances in menopausal women: aetilogy and practical aspects. Maturitas 2015; 81: 406-9.Parandavar N, Abdali K, Keshtgar S. The effect of melatonin on climacteric symptoms in menopausal women; a double - blind, randomized controlled, clinical trial. Iran J Public Health 2014; 43: 1405-16.